Qiagen

Bioinformatics Market Size is Projected to Hit 24.07 Bn by 2028, With at a 12.1% CAGR by 2022-2028 | Brandessence Market Research

Retrieved on: 
Tuesday, September 26, 2023
The Comprehensive Guide to Board Wargaming, Data management, Database, DNA, Drug development, Information technology, Genetics, Genomics, Diverticulitis, Personal Data Privacy and Security Act of 2009, Privacy, Bioinformatics, Research, Thermo Fisher Scientific, Confidentiality, Proteomics, Nanopore sequencing, Drug, Security, EMA, Data analysis, Investment, Mining, Anemia, Drug discovery, HPV, Porter's five forces analysis, Growth, FDA, Epidemiology, Software, Risk management, Pharmaceutical industry, Network equipment provider, Video game, Vaccine, Illumina, Qiagen

The escalating demand for integrated bioinformatics systems in proteomics and genomics is also bolstering market growth.

Key Points: 
  • The escalating demand for integrated bioinformatics systems in proteomics and genomics is also bolstering market growth.
  • However, challenges persist in the form of a shortage of skilled professionals and the high implementation costs associated with bioinformatics software.
  • Competitive Rivalry within the Industry:
    High Threat: The bioinformatics market is highly competitive, with numerous well-established players vying for market share.
  • The bioinformatics market is poised for remarkable growth, driven by technological advancements, increasing research endeavors, and a burgeoning focus on personalized medicine.

EQS-News: Rentschler Biopharma appoints Benedikt von Braunmuehl as Chief Executive Officer and Tom Roberts as President and General Manager U.S.

Retrieved on: 
Monday, September 25, 2023
Invictus, 3M, Non-U.S. operators of the M60 Patton, BS, Senior, Denison University, Supervisory board, Boston, MBA, Medicine, Qiagen, CDMO, KCI, Acquisition, Patient, Indiana Wesleyan University, Executive Committee, Roche, Biology, Growth, S-1 Executive Committee, Management, Industrial design, Medicover Hospitals, Greater Boston

Rentschler Biopharma appoints Benedikt von Braunmuehl as Chief Executive Officer and Tom Roberts as President and General Manager U.S.

Key Points: 
  • Rentschler Biopharma appoints Benedikt von Braunmuehl as Chief Executive Officer and Tom Roberts as President and General Manager U.S.
  • Prior to joining Rentschler Biopharma, Mr. von Braunmuehl served as CEO of HMNC Brain Health in Munich, Germany, where he transformed a research-focused organization to a clinical-stage biopharma company.
  • Prof. Dr. Nikolaus F. Rentschler, Chairman of the Supervisory Board of Rentschler Biopharma SE, said: “I would like to warmly welcome Benedikt von Braunmuehl to Rentschler Biopharma.
  • Mr. von Braunmuehl is the perfect fit for leading Rentschler Biopharma, to continue transforming innovative ideas into life-saving biopharmaceuticals in the future.

Rentschler Biopharma appoints Benedikt von Braunmuehl as Chief Executive Officer

Retrieved on: 
Tuesday, September 19, 2023
Invictus, 3M, Non-U.S. operators of the M60 Patton, BS, Senior, Denison University, Supervisory board, Boston, MBA, Medicine, Qiagen, CDMO, KCI, Acquisition, Patient, Indiana Wesleyan University, Executive Committee, Roche, Biology, Growth, S-1 Executive Committee, Management, Industrial design, Medicover Hospitals, Greater Boston

Benedikt von Braunmuehl, a transformational leader with a 30-year track record in the global healthcare industry, is named CEO Rentschler Biopharma SE

Key Points: 
  • Benedikt von Braunmuehl, a transformational leader with a 30-year track record in the global healthcare industry, is named CEO Rentschler Biopharma SE
    Company also announces appointment of Tom Roberts, an entrepreneurial trailblazer with over 20 years of experience, as President of Rentschler Biopharma Inc. and General Manager U.S.
    LAUPHEIM, Germany and STEVENAGE, United Kingdom and MILFORD, Mass., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Rentschler Biopharma SE, a leading global contract development and manufacturing organization (CDMO) for biopharmaceuticals, today announced that the company has hired Benedikt von Braunmuehl as Chief Executive Officer (CEO).
  • Prior to joining Rentschler Biopharma, Mr. von Braunmuehl served as CEO of HMNC Brain Health in Munich, Germany, where he transformed a research-focused organization to a clinical-stage biopharma company.
  • Prof. Dr. Nikolaus F. Rentschler, Chairman of the Supervisory Board of Rentschler Biopharma SE, said: “I would like to warmly welcome Benedikt von Braunmuehl to Rentschler Biopharma.
  • I very much look forward to working with Benedikt von Braunmuehl to continue to create value sustainably, for our clients and patients.”
    Benedikt von Braunmuehl, CEO, Rentschler Biopharma SE, commented: “I am excited to have the opportunity to lead Rentschler Biopharma.

Global Breast Biopsy Market - Growing Adoption of Liquid Biopsy Drives Significant Growth - ResearchAndMarkets.com

Retrieved on: 
Tuesday, August 15, 2023
Health, Women, Oncology, Consumer, Infection, CNB, CT, Prevalence, Hologic, Liquid biopsy, VAB, MRI, US, Medtronic, FNAB, Growth, Ageing, Mammography, Female, Breast cancer, Roche, Medical imaging, Qiagen

Growth in the global breast biopsy market was supported by factors such as increasing prevalence of breast cancer and rising female population aged 65 or above.

Key Points: 
  • Growth in the global breast biopsy market was supported by factors such as increasing prevalence of breast cancer and rising female population aged 65 or above.
  • Growing adoption of liquid biopsy is likely to have a positive impact on the global breast biopsy market.
  • In 2022, the dominant share of global breast biopsy market was held by core needle biopsy (CNB), followed by vacuum assisted biopsy (VAB).
  • The global breast biopsy market by image guided technology can be segmented as follows: mammography guided stereotactic biopsy, ultrasound guided biopsy, MRI guided biopsy and CT guided biopsy.

Global In-Vitro Diagnostics Market Report 2023-2028: Rising Demand for Automated IVD Systems in Hospitals & Laboratories - ResearchAndMarkets.com

Retrieved on: 
Monday, August 14, 2023
Infectious Diseases, Health, Other Health, Infection, Hepatitis, Laboratory, Prevalence, Medicine, Siemens Healthineers, Bio-Rad Laboratories, Hospital, Tuberculosis, BioMérieux, IVD, Conditional sentence, Growth, Pneumonia, Porter's five forces analysis, Medical device, Qiagen

The "In-Vitro Diagnostics Market: Trends, Opportunities and Competitive Analysis 2023-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "In-Vitro Diagnostics Market: Trends, Opportunities and Competitive Analysis 2023-2028" report has been added to ResearchAndMarkets.com's offering.
  • The global in-vitro diagnostics market is expected to witness a promising future, with opportunities in the hospitals, laboratories, and home care end-use industries.
  • The market is projected to reach an estimated value of $127.3 billion by 2028, growing at a CAGR of 5% from 2023 to 2028.
  • The major drivers of this growth are the increasing prevalence of chronic diseases and the rising demand for automated IVD systems in hospitals and laboratories to ensure accurate, error-free, and efficient diagnoses.

Nomic Bio Appoints Byron Hewett to its Board of Directors

Retrieved on: 
Wednesday, June 28, 2023
Science, Biotechnology, Nanotechnology, Research, Pharmaceutical, Health, Technology, Genetics, Qiagen, Growth, Drug development, SomaLogic, Bio, Proteomics, Management

Nomic Bio, a pioneering protein profiling company, today announced the appointment of Byron Hewett to its board of directors.

Key Points: 
  • Nomic Bio, a pioneering protein profiling company, today announced the appointment of Byron Hewett to its board of directors.
  • Hewett brings invaluable operational and strategic expertise to guide Nomic Bio through its crucial years of growth.
  • “We are thrilled to welcome Byron to Nomic’s board of directors as we commercialize and continue to scale our nELISA platform,” said Milad Dagher, CEO and co-founder of Nomic Bio.
  • “I have been following the progress of Nomic Bio for several years now and I’ve been quite impressed,” said Hewett.

Global Clinical Diagnostics Market Opportunities and Challenges 2023-2028 - ResearchAndMarkets.com

Retrieved on: 
Friday, June 23, 2023
Infectious Diseases, Biotechnology, Health, Qiagen, Abbott Laboratories, Row, Siemens Healthineers, Prevalence, Thermo Fisher Scientific, Infection, Roche, Medical device, Medical imaging

The clinical diagnostics market is growing steadily, due to the increasing prevalence of infectious diseases, the rising demand for early and accurate disease diagnosis, and technological advances.

Key Points: 
  • The clinical diagnostics market is growing steadily, due to the increasing prevalence of infectious diseases, the rising demand for early and accurate disease diagnosis, and technological advances.
  • Major players in the clinical diagnostics market include Roche Diagnostics, Abbott Laboratories, Siemens Healthineers, and Thermo Fisher Scientific Inc.
  • This report aims to provide a comprehensive study of the global market for clinical diagnostics, both quantitative and qualitative data, to help executives develop corporate growth strategies, assess the market landscape, analyze their positions in the current marketplace, and make informed business decisions regarding clinical diagnostics.
  • This report also categorizes the global clinical diagnostic market based on four geographic regions: North America, Europe, Asia-Pacific and the Rest of the World (RoW).

World COVID-19 Testing Markets Analysis Report 2023: Insurance Coverage, Multiplex Testing, EUAs and Public Health Emergency Expiration, & New Variants On the Horizon - ResearchAndMarkets.com

Retrieved on: 
Tuesday, June 13, 2023
Biotechnology, Health, COVID-19, Medical Supplies, Test market, Test Site, Abbott, Thermo Fisher Scientific, Roche, Segment, Danaher, QuidelOrtho, Qiagen, PerkinElmer, 2020 Global Rapid Rugby season, OraSure Technologies, BioMérieux, Distribution, Immunoassay, Laboratory, Country, Food delivery, Pharmaceutical industry

Immunoassay COVID-19 Vendor Market Share, by Vendor (Abbott, Beckman Coulter-Danaher, Becton Dickson, Diasorin, Fujirebio Diagnostics, PerkinElmer, QuidelOrtho, Roche, Siemens, ThermoFisher, Others), 2022 (%)

Key Points: 
  • Immunoassay COVID-19 Vendor Market Share, by Vendor (Abbott, Beckman Coulter-Danaher, Becton Dickson, Diasorin, Fujirebio Diagnostics, PerkinElmer, QuidelOrtho, Roche, Siemens, ThermoFisher, Others), 2022 (%)
    Molecular COVID-19 Vendor Market Share, by Vendor (Abbott, bioMerieux, Cepheid-Danaher, Hologic, Orasure Technologies, PerkinElmer, Qiagen, QuidelOrtho, Roche, ThermoFisher, Others), 2022 (%)
    Global IVD Market (COVID-19 Assays and Instruments, Excluding COVID-19 Assays and Instruments), 2019-2022, ($MN)
    Global IVD Market, Distribution by Performance Segment (COVID-19 Assays and Instruments, Excluding COVID-19 Assays and Instruments), 2022 (%)
    Global COVID-19 Testing by Test Site (Laboratory, Rapid/Near Patient) Sales by Segment, 2022-2027
    Global COVID-19 IVD Market by Test Site, 2020-2022 and Forecast Through 2027 ($MN)
    Global Lab-based COVID-19 Testing Market, Distribution of Sales by Segment (Immunoassay, Molecular), 2022-2027 ($MN)
    Global Rapid-based COVID-19 Testing Market, Distribution of Sales by Segment (Immunoassay, Molecular), 2022-2027 ($MN)
    Global COVID-19 IVD Market by Test Method, 2020-2022 and Forecast Through 2027 ($MN)
    Estimated Global COVID-19 Testing Market by Region, 2020-2022
    COVID-19 Testing Market by Country, Estimated 2022 ($M)
    Top 10 COVID-19 Vendors and Global Market Share, by Vendor (Abbott, bioMerieux, Danaher, Hologic, PerkinElmer, Qiagen, QuidelOrtho, Roche, Siemens, ThermoFisher, Others), 2022

BioTools Innovator Announces Top 19 Life Sciences Companies Named to the 2023 Cohort

Retrieved on: 
Tuesday, June 6, 2023
Professional Services, Health, Health Technology, Start-Up, Research, Science, Biotechnology, Biomedical Advanced Research and Development Authority, Drug development, Therapy, Abraxis BioScience, Johnson & Johnson, Danaher, RCT, Thermo Fisher Scientific, Catalent, Mass spectrometry, AstraZeneca, Standard BioTools, Qiagen, Microfluidics, Becton, Dickinson and Company headquarters, Development, Research Corporation, Mesa, Vitrification, Cell, Growth, BARDA, Black Snow, Pharmaceutical industry, Management, Fine chemical, Mobile phone, Caesarea, Genentech, Agilent Technologies

BioTools Innovator , the first accelerator focused on life science tools and diagnostics to advance cutting-edge research and improve human health, announced today that 19 companies have been selected to participate in its annual program.

Key Points: 
  • BioTools Innovator , the first accelerator focused on life science tools and diagnostics to advance cutting-edge research and improve human health, announced today that 19 companies have been selected to participate in its annual program.
  • The BioTools Innovator Accelerator is a four-month virtual program providing startups with in-depth, customized mentorship and support from senior industry leaders, funding opportunities, and engagement with peers and advisors.
  • From a pool of more than 260 applicants from 31 countries and 34 U.S. states, the top 19 companies were selected to participate in the BioTools Innovator Accelerator.
  • “BioTools Innovator was launched to provide life science entrepreneurs guidance from experienced industry leaders in biotools and diagnostics to help them be successful,” said Kathryn Zavala, managing director of BioTools Innovator.

Navigate BioPharma Services, Inc. launches new multiplex digital PCR assay for comprehensive quantification of up to 5 different CAR-T transgenes

Retrieved on: 
Thursday, June 1, 2023
Business development, Drug development, Cancer, Multimedia, Associate, Qiagen, CAR, Novartis, The Queen's Award for Enterprise: Innovation (Technology) (2007), Navigation, PCR, Vaccine

These assays are based on the Qiagen QIAcuity digital PCR System, which offers a powerful yet easy-to-use digital PCR experience through its unique nanoplate system.

Key Points: 
  • These assays are based on the Qiagen QIAcuity digital PCR System, which offers a powerful yet easy-to-use digital PCR experience through its unique nanoplate system.
  • The new multiplex digital PCR assay enables simultaneous measurement of the number, function and persistence of CAR-T cells in clinical blood and bone marrow samples, without the need for a standard curve.
  • The assay can help clinicians monitor response or safety events during clinical trials to enable the development of new therapies.
  • Over the past decade, Navigate BioPharma has built and developed its exclusive library of assays, methodologies, and biomarker solutions.